DK2963125T3 - Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret - Google Patents

Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret Download PDF

Info

Publication number
DK2963125T3
DK2963125T3 DK14751787.4T DK14751787T DK2963125T3 DK 2963125 T3 DK2963125 T3 DK 2963125T3 DK 14751787 T DK14751787 T DK 14751787T DK 2963125 T3 DK2963125 T3 DK 2963125T3
Authority
DK
Denmark
Prior art keywords
nrf2
stabilized
cancer
treatment
therapeutic agent
Prior art date
Application number
DK14751787.4T
Other languages
English (en)
Inventor
Johji Inazawa
Jun Inoue
Shinsuke Yamamoto
Tatsuyuki Kawano
Ken-Ichi Kozaki
Original Assignee
Univ Nat Corp Tokyo Medical & Dental
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nat Corp Tokyo Medical & Dental filed Critical Univ Nat Corp Tokyo Medical & Dental
Application granted granted Critical
Publication of DK2963125T3 publication Critical patent/DK2963125T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
DK14751787.4T 2013-02-15 2014-02-17 Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret DK2963125T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013027399 2013-02-15
PCT/JP2014/053594 WO2014126233A1 (ja) 2013-02-15 2014-02-17 マイクロｒｎａの測定方法、並びに、がん治療剤及びこれを含有するがん治療のための医薬組成物

Publications (1)

Publication Number Publication Date
DK2963125T3 true DK2963125T3 (da) 2020-10-12

Family

ID=51354231

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14751787.4T DK2963125T3 (da) 2013-02-15 2014-02-17 Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret

Country Status (6)

Country Link
US (2) US9994843B2 (da)
EP (1) EP2963125B1 (da)
JP (2) JP6587142B2 (da)
DK (1) DK2963125T3 (da)
ES (1) ES2828510T3 (da)
WO (1) WO2014126233A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
CN106676196B (zh) * 2017-03-10 2019-05-07 上海核盾生物科技有限公司 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒
EP3479845A1 (en) * 2017-11-06 2019-05-08 Stalicla S.A. Challenge test for diagnosing subtype of autism spectrum disease
US20220202846A1 (en) 2019-01-10 2022-06-30 Osaka University Immunostimulating composition
WO2020150480A1 (en) * 2019-01-17 2020-07-23 Board Of Regents, The University Of Texas System Methods for treatment of lung cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2302055T3 (da) * 2004-11-12 2014-10-13 Asuragen Inc Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler
DE602005022936D1 (de) 2004-12-20 2010-09-23 Genentech Inc Pyrrolidine als inhibitoren von iap
EP2198050A1 (en) * 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009044899A1 (ja) * 2007-10-03 2009-04-09 Kyowa Hakko Kirin Co., Ltd. 細胞の増殖を制御する核酸
JP5116026B2 (ja) 2008-01-23 2013-01-09 富士フイルム株式会社 癌の検出方法および癌抑制剤
WO2009120712A2 (en) * 2008-03-24 2009-10-01 New York University Compositions and methods for diagnosing and treating melanoma
JP5513375B2 (ja) 2008-05-07 2014-06-04 北海道公立大学法人 札幌医科大学 癌の検出方法および検出用キット、ならびに癌治療剤
WO2011111715A1 (ja) 2010-03-09 2011-09-15 協和発酵キリン株式会社 細胞周期を制御する核酸
JPWO2011125245A1 (ja) 2010-04-05 2013-07-08 公益財団法人がん研究会 ｍｉＲＮＡを用いた小細胞肺癌の予後予測方法、小細胞肺癌治療方法、小細胞肺癌予後改善方法、及び小細胞肺癌治療剤のスクリーニング方法
WO2012121178A1 (ja) * 2011-03-04 2012-09-13 独立行政法人国立がん研究センター 腫瘍血管形成阻害剤
WO2012145743A1 (en) * 2011-04-22 2012-10-26 University Of Houston Microrna-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
BR112013032232A2 (pt) 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
JP2013028575A (ja) 2011-07-29 2013-02-07 Toray Ind Inc Ｋｅａｐ１タンパク質結合化合物、該Ｋｅａｐ１タンパク質結合化合物とＫｅａｐ１タンパク質の複合体の結晶及びその製造方法
US20150216892A1 (en) * 2012-08-03 2015-08-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9315809B2 (en) * 2012-08-29 2016-04-19 City Of Hope Differentially expressed microRNA molecules for the treatment and diagnosis of cancer

Also Published As

Publication number Publication date
US20190367915A1 (en) 2019-12-05
WO2014126233A1 (ja) 2014-08-21
US9994843B2 (en) 2018-06-12
EP2963125A4 (en) 2016-11-02
JPWO2014126233A1 (ja) 2017-02-02
EP2963125A1 (en) 2016-01-06
JP6587142B2 (ja) 2019-10-09
EP2963125B1 (en) 2020-09-30
ES2828510T3 (es) 2021-05-26
US20160053257A1 (en) 2016-02-25
JP2018143248A (ja) 2018-09-20
JP6745071B2 (ja) 2020-08-26
US10876115B2 (en) 2020-12-29

Similar Documents

Publication Publication Date Title
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3057628T3 (da) Injektionsindretning til terapeutisk middel
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
BR112016027041A2 (pt) Combinações farmacêuticas para tratamento do câncer
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK3572410T3 (da) Dioxolananaloger af uridin til behandling af cancer
DK2764881T3 (da) System til medicinsk behandling
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3089749T3 (da) Kombinerede præparater til behandling af cancer
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK2825558T3 (da) Kombinationsterapi til behandling af ovariecancer
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte
HK1222548A1 (zh) 治療惡性腫瘤的藥物組合
DK3253208T3 (da) Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK2974728T3 (da) Terapeutisk middel til meibomsk dysfunktion
DK3077544T3 (da) Rationelt-baseret design af en målrettet terapi til cancer
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
DK2963125T3 (da) Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret
DK2964185T3 (da) Præparater til behandlingen af søvnrelaterede luftvejslidelser
DK3071192T3 (da) Curcuphenolforbindelse til anvendelse i behandling af cancer